Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Dr. Davids on the Combination of Ibrutinib and Obinutuzumab in CLL

January 3rd 2018

Matthew S. Davids, MD, MMSc, associate director, Dana-Farber Cancer Institute, Center for Chronic Lymphocytic Leukemia, discusses the combination of ibrutinib (Imbruvica) and obinutuzumab (Gazyva) for patients with relapsed or refractory chronic lymphocytic leukemia (CLL).

Dr. Rogers Discusses Obinutuzumab, Ibrutinib, and Venetoclax Combination in CLL

December 22nd 2017

Kerry Rogers, MD, assistant professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the initial results of the phase II treatment-naïve cohort in a phase Ib/II study of obinutuzumab (Gazyva), ibrutinib (Imbruvica), and venetoclax (Vencelxta) in chronic lymphocytic leukemia (CLL).

Dr. Logan Discusses Treatment Options in CLL

December 19th 2017

Aaron Logan, MD, PhD, assistant professor of clinical medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses treatment options for patients with chronic lymphocytic leukemia.

Dr. Davids on Ibrutinib Plus FCR in Younger Patients With CLL

December 16th 2017

Matthew S. Davids, MD, MMSc, Associate Director, Dana-Farber Cancer Institute, Center for Chronic Lymphocytic Leukemia, discusses ibrutinib plus FCR in younger patients with CLL.

Promising Results in CLL for Frontline Ibrutinib Plus Chemoimmunotherapy

December 14th 2017

Adding ibrutinib to a standard frontline chemoimmunotherapy for chronic lymphocytic leukemia induced negative minimum residual disease status in bone marrow for 83% of patients.

Combinations Have Potential to Shift CLL Treatment Paradigm

December 13th 2017

Richard Furman, MD, discusses the current management of chronic lymphocytic leukemia and the future of combinations, including venetoclax and ibrutinib, for this patient population.

Dr. Flinn on Venetoclax and Obinutuzumab in CLL

December 12th 2017

Ian Flinn, MD, Director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the safety, efficacy, and MRD negativity of a combination of venetoclax (Venclexta) and obinutuzumab (Gazyva) in patients with previously untreated chronic lymphocytic leukemia (CLL) during the 2017 ASH Annual Meeting. Overall, 32 patients were treated with this combination in the first-line setting. Investigators saw high complete remission (CR) rates, with over two-thirds of patients experiencing a CR, Flinn explains. In addition, high MRD negativity rates were also demonstrated, in both the peripheral blood and the bone marrow.

CLL in the Era of Targeted Therapies

December 12th 2017

Over the past few years, remarkable advances have been achieved in the field of chronic lymphocytic leukemia by rationally targeting pathways overexpressed and used by the malignant clone for proliferation and survival.

Venetoclax/Rituximab Hits Over 80% 2-Year PFS Rate in CLL

December 12th 2017

The combination of venetoclax and rituximab reduced the risk of disease progression or death by 83% versus bendamustine plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.

Rituximab Leads to Faster Response in CLL, But PFS Not Improved

December 11th 2017

Despite a faster time to complete remission, the addition of rituximab (Rituxan) to ibrutinib (Imbruvica) did not improve PFS or overall survival OS compared with ibrutinib alone in patients with CLL.

Ibrutinib/Venetoclax Combo Impresses in Early CLL Data

December 10th 2017

The combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) elicited a complete response (CR) or CR with incomplete hematologic recovery rate of 47% for patients with relapsed/refractory chronic lymphocytic leukemia.

Dr. Rogers Discusses Early Intervention With Ibrutinib in CLL

December 10th 2017

Kerry Rogers, MD, Assistant Professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses a phase II trial of early intervention with ibrutinib (Imbruvica) in patients with asymptomatic, high-risk chronic lymphocytic leukemia (CLL) during the 2017 ASH Annual Meeting.

Dr. Barrientos Discusses Ibrutinib in Elderly Populations With CLL

December 6th 2017

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses ibrutinib (Imbruvica) in elderly populations with CLL.

Treatment Strategies Expanding for Elderly Patients With CLL

November 27th 2017

Jacqueline Claudia Barrientos, MD, discusses the appropriate treatment strategies for elderly patients with chronic lymphocytic leukemia.

Dr. Rai Discusses CLL in Older Populations

November 22nd 2017

Kanti R. Rai, MD, discusses older populations with chronic lymphocytic leukemia.

Umbralisib, Ublituximab, Ibrutinib Triplet Reaches 100% Response in CLL

November 14th 2017

Loretta J. Nastoupil, MD, discusses the study of the triplet of ublituximab, umbralisib (TGR-1202) and ibrutinib in CLL.

Acalabrutinib Among Exciting Options Emerging in CLL

November 14th 2017

Jacqueline Claudia Barrientos, MD, discusses emerging treatment options in CLL.

Dr. Barrientos Discusses the Management of Elderly Patients with CLL

November 14th 2017

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, discusses the management of elderly patients with chronic lymphocytic leukemia (CLL).

Profiling CLL Patients Likely to Progress on Available Agents

November 9th 2017

The next frontier in advancing the field of chronic lymphocytic leukemia (CLL) is identifying patients who will not experience long-term progression-free survival on novel agents.

Dr. Awan on the Importance of FISH Testing in CLL

November 8th 2017

Farrukh Awan, MBBS, associate professor, The Ohio State University Comprehensive Cancer Center, discusses the importance of fluorescence in situ hybridization (FISH) testing for patients with chronic lymphocytic leukemia (CLL).